Plagued by the financial impact of its manufacturing deficiencies and suffering from generic competition for its antihistamine Claritin (loratadine), Schering-Plough Corp. revealed in a filing with the Securities and Exchange Commission last week that it did not have sufficient cash flow from operations to cover its domestic expenses for the year. But the troubled firm does have US4.1 billion in cash and cash equivalents to bankroll expenses for the rest of the year.
展开▼
机译：先灵-雅（Schering-Plough Corp.）因其制造缺陷的财务影响以及其抗组胺药克拉里汀（氯雷他定）的仿制药竞争而遭受困扰，上周在美国证券交易委员会（Securities and Exchange Commission）的一份文件中披露，该公司从运营到运营的现金流量不足。支付当年的国内开支。但是这家陷入困境的公司在今年余下时间的确拥有41亿美元的现金和现金等价物。
展开▼
